S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:MBII

Marrone Bio Innovations (MBII) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.80
$0.80
50-Day Range
$0.80
$0.80
52-Week Range
$0.55
$1.55
Volume
38 shs
Average Volume
919,497 shs
Market Capitalization
$145.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MBII stock logo

About Marrone Bio Innovations Stock (NASDAQ:MBII)

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

MBII Stock News Headlines

Third Harmonic Bio Inc THRD
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Kala Bio Inc KALA
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Tourmaline Bio Inc TRML
Q2 2023 Bio Path Holdings Inc Earnings Call
MYCOF Mydecine Innovations Group Inc.
REII Renewable Innovations, Inc.
See More Headlines
Receive MBII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Agricultural Chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MBII
Fax
N/A
Employees
153
Year Founded
N/A

Profitability

Net Income
$-16,550,000.00
Pretax Margin
-47.12%

Debt

Sales & Book Value

Annual Sales
$44.31 million
Book Value
$0.17 per share

Miscellaneous

Free Float
173,259,000
Market Cap
$145.56 million
Optionable
Not Optionable
Beta
0.36
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Kevin R. Helash (Age 57)
    CEO & Director
    Comp: $416.64k
  • Dr. Pamela G. Marrone Ph.D. (Age 65)
    Founder, Advisor & Non-Employee Director
    Comp: $254.58k
  • Ms. Linda V. Moore (Age 75)
    Chief Compliance Officer, Chief Legal Officer & Sec.
    Comp: $316.74k
  • Mr. LaDon Johnson CPA
    CPA, Interim Chief Financial Officer
  • Dr. Amit Vasavada Ph.D. (Age 67)
    Sr. VP of Research Devel. & Chief Technical Officer
  • Andre Trepanier
    Director of Marketing
  • Mr. Barner Jones
    Director of National Sales & Account Management
  • Mr. Matti Tiainen (Age 33)
    Sr. VP of International Sales
  • Mr. Keith J. Pitts (Age 58)
    Sr. VP of Regulatory & Gov. Affairs and Chief Sustainability Officer

MBII Stock Analysis - Frequently Asked Questions

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations, Inc. (NASDAQ:MBII) posted its earnings results on Wednesday, November, 10th. The basic materials company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.03). The basic materials company earned $9.86 million during the quarter, compared to analysts' expectations of $10.79 million. Marrone Bio Innovations had a negative trailing twelve-month return on equity of 70.87% and a negative net margin of 47.07%. During the same period in the previous year, the firm earned ($0.04) earnings per share.

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Ekso Bionics (EKSO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Enerplus (ERF), ADMA Biologics (ADMA), Great Panther Mining (GPL), Organigram (OGI), Aeterna Zentaris (AEZS).

This page (NASDAQ:MBII) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners